1 |
Frei, B., Stocker, R., England, L., and Ames, E. N., Plenum Press, New Work, pp 155-164 (1991)
|
2 |
Torres, M. D., Canal, J. R., and Perez, C., Oxidative stress in normal and diabetic rats. Physiol. Res. 48, 203-208 (1999)
|
3 |
Lehman, J. M., Moore, L. B., Smith- Oliver, T. A., Wilkison, W. O., Willson T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995)
DOI
ScienceOn
|
4 |
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., and Horikoshi, H., Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37, 1549-1558 (1988)
DOI
ScienceOn
|
5 |
Cantello, B. C. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Smith, S. A., and Thurlby, P. L., [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994)
DOI
ScienceOn
|
6 |
Maxwell, S. R., Thomason, H., Sandler, D., Leguen, C., Baxter, M. A., Thorpe, G. H., Jones, A. F., and Barnett, A. H. Antioxidant status in patients with uncomplicated insulindependent and non-insulin-dependent diabetes mellitus., Eur. J. Clin. Inest., 27, 484-490 (1997)
DOI
ScienceOn
|
7 |
Meguro, K. and Fujita, T., Thiazolidinedione derivatives, and their medicinal compositions. EP 0155845 (1985)
|